MarketCap
Facebook
X
TelegramQuarterly report 2025-Q4
added 02-06-2026
Canopy Growth Corporation Total Current Liabilities 2011-2026 | CGC
Annual Total Current Liabilities Canopy Growth Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 94.4 M | 235 M | 804 M | 679 M | 284 M | 421 M | - | - | - | - | - | - | - | - | - |
All numbers in CAD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 804 M | 94.4 M | 420 M |
Total Current Liabilities of other stocks in the Drug manufacturers industry
| Issuer | Total Current Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Aerie Pharmaceuticals
AERI
|
125 M | - | - | $ 754 M |  USA |
 |
Alimera Sciences
ALIM
|
21.9 M | - | - | $ 142 M | USA |
 |
AcelRx Pharmaceuticals
ACRX
|
2.65 M | - | 7.5 % | $ 6.35 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
11.4 M | - | 0.86 % | $ 117 M | USA |
 |
Agile Therapeutics
AGRX
|
20.8 M | - | 10.11 % | $ 58.2 M | USA |
 |
Catalent
CTLT
|
1.03 B | - | - | $ 11.5 B | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
48.8 M | - | - | $ 2.06 B |  France |
 |
Evolus
EOLS
|
75.3 M | $ 5.88 | 5.1 % | $ 379 M | USA |
 |
China Pharma Holdings
CPHI
|
5.02 M | $ 0.59 | 1.55 % | $ 10.3 M |  China |
 |
DURECT Corporation
DRRX
|
27 M | - | - | $ 50.1 M | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
31.6 M | $ 3.66 | -0.27 % | $ 51.5 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
111 M | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
539 M | - | - | $ 28.9 M |  Irlanda |
 |
Evoke Pharma
EVOK
|
9.65 M | - | - | $ 36.6 M | USA |
 |
Harrow Health
HROW
|
96.3 M | $ 37.35 | -4.78 % | $ 1.37 B | USA |
 |
Athenex
ATNX
|
115 M | - | -23.39 % | $ 1.76 M | USA |
 |
Jupiter Wellness
JUPW
|
9.4 M | - | - | $ 33.6 M | USA |
 |
Emergent BioSolutions
EBS
|
651 M | $ 8.47 | -3.42 % | $ 434 M | USA |
 |
Assertio Holdings
ASRT
|
93.4 M | $ 11.9 | -1.41 % | $ 845 M | USA |
 |
Bausch Health Companies
BHC
|
4.3 B | $ 5.62 | -0.18 % | $ 2.05 B |  Canada |
 |
Lannett Company
LCI
|
105 M | - | 1.15 % | $ 7.11 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
23 M | - | - | $ 193 M | Canada |
 |
Organogenesis Holdings
ORGO
|
77.5 M | $ 2.95 | 2.79 % | $ 388 M | USA |
 |
Perrigo Company plc
PRGO
|
1.01 B | $ 11.31 | -3.29 % | $ 1.57 B | USA |
 |
TherapeuticsMD
TXMD
|
6.85 M | $ 2.19 | 1.4 % | $ 22.9 M | USA |
 |
ProPhase Labs
PRPH
|
16.1 M | - | - | $ 5.07 M | USA |
 |
Veru
VERU
|
11.9 M | $ 2.52 | 0.4 % | $ 340 M | USA |
 |
Viatris
VTRS
|
6.75 B | $ 14.61 | -0.68 % | $ 17.5 B | USA |
 |
Radius Health
RDUS
|
94.8 M | - | - | $ 1.42 B | USA |
 |
Rockwell Medical
RMTI
|
16.6 M | $ 0.89 | -0.77 % | $ 20.8 M | USA |
 |
cbdMD
YCBD
|
8.62 M | $ 0.76 | -1.32 % | $ 3.28 M | USA |
 |
Pacira BioSciences
PCRX
|
310 M | $ 22.83 | -0.13 % | $ 1.06 B | USA |
 |
PetIQ
PETQ
|
190 M | - | 1.64 % | $ 400 M | USA |
 |
OptiNose
OPTN
|
177 M | - | - | $ 1.08 B | USA |
 |
PLx Pharma
PLXP
|
11.9 M | - | -27.8 % | $ 2.56 M | USA |
 |
Recro Pharma
REPH
|
50 M | - | -4.76 % | $ 65.3 M | USA |
 |
Relmada Therapeutics
RLMD
|
12.2 M | $ 4.35 | -8.83 % | $ 131 M | USA |
 |
SCYNEXIS
SCYX
|
5.73 M | $ 0.78 | 0.27 % | $ 38.9 M | USA |
 |
Solid Biosciences
SLDB
|
30.3 M | $ 5.83 | -5.05 % | $ 238 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
4.1 M | $ 2.65 | -5.47 % | $ 3.29 M | USA |
 |
Tricida
TCDA
|
29.5 M | - | - | $ 3.25 M | USA |
 |
Tilray
TLRY
|
433 M | $ 7.14 | -2.26 % | $ 4.41 B | Canada |
 |
Zynerba Pharmaceuticals
ZYNE
|
9.17 M | - | - | $ 55.5 M | USA |